Creative Medical Technology Holdings, Inc. (CELZ)
CELZ moved a median of 0.00% 30 minutes after news, and -1.96% by the close. How CELZ actually reacts to news — the realized, point-in-time move the market made, measured across 103 labeled events over the last three years with zero look-ahead.
CELZ’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 97 |
| 30-min | 0.00% | 49% | 99 |
| 60-min | -0.64% | 37% | 101 |
| to close | -1.96% | 32% | 102 |
| Middle 50% of CELZ reactions | -2.59% to +1.96% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 103 |
Half of all Creative Medical Technology Holdings, Inc. news events land between -2.59% and +1.96% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CELZ moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CELZ's baseline. Nothing else.
Recent CELZ events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K CREATIVE MEDICAL TECHNOL For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | -1.96% | +1.00% | |
| Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing | Press release | GlobeNewswire | +1.82% | +2.04% | |
| Form 8-K CREATIVE MEDICAL TECHNOL For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | -0.90% | |
| Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning | Press release | GlobeNewswire | -4.80% | +2.40% | |
| Form 10-Q CREATIVE MEDICAL TECHNOL For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.85% | — | |
| Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms | Press release | GlobeNewswire | -2.15% | -0.86% | |
| Form EFFECT CREATIVE MEDICAL TECHNOL | SEC filing · Form EFFECT | SEC EDGAR | -3.16% | -1.62% | |
| Form S-3 CREATIVE MEDICAL TECHNOL | SEC filing · Form S-3 | SEC EDGAR | +1.11% | +0.27% | |
| Form DEF 14A CREATIVE MEDICAL TECHNOL For: Aug 28 | SEC filing · Form DEF | SEC EDGAR | -0.23% | -3.29% | |
| Form 8-K CREATIVE MEDICAL TECHNOL For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -1.56% | -6.50% | |
| Creative Medical Technology Holdings Issues Mid-Year Update | Press release | GlobeNewswire | -7.71% | -6.62% | |
| Form PRE 14A CREATIVE MEDICAL TECHNOL For: Jul 01 | SEC filing · Form PRE | SEC EDGAR | +5.07% | -3.20% | |
| Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds | Press release | GlobeNewswire | -19.89% | -47.94% | |
| Form RW CREATIVE MEDICAL TECHNOL | SEC filing · Form RW | SEC EDGAR | +53.06% | -44.44% | |
| Form S-1/A CREATIVE MEDICAL TECHNOL | SEC filing · Form S-1 | SEC EDGAR | -10.08% | -37.19% | |
| Form S-1 CREATIVE MEDICAL TECHNOL | SEC filing · Form S-1 | SEC EDGAR | -3.45% | -17.24% | |
| Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain | Press release | GlobeNewswire | -2.64% | -14.98% | |
| Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards | Press release | GlobeNewswire | +0.00% | -6.28% | |
| Form 10-Q CREATIVE MEDICAL TECHNOL For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.09% | -3.54% | |
| Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies | Press release | GlobeNewswire | -5.78% | -0.89% | |
| Form 10-K/A CREATIVE MEDICAL TECHNOL For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +3.64% | |
| Form 10-K CREATIVE MEDICAL TECHNOL For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -2.62% | |
| Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline | Press release | GlobeNewswire | +3.76% | +3.76% | |
| Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain | Press release | GlobeNewswire | -7.89% | -20.18% | |
| Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative | Press release | GlobeNewswire | -1.78% | +7.21% | |
| Form 8-K CREATIVE MEDICAL TECHNOL For: Dec 26 | SEC filing · Form 8-K | SEC EDGAR | -1.01% | +0.00% | |
| Form 8-K CREATIVE MEDICAL TECHNOL For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | -0.94% | |
| Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point | Press release | GlobeNewswire | -0.24% | +1.20% | |
| Form EFFECT CREATIVE MEDICAL TECHNOL | SEC filing · Form EFFECT | SEC EDGAR | -1.86% | -1.40% | |
| Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 | Press release | GlobeNewswire | -2.42% | -10.69% | |
| Form S-3 CREATIVE MEDICAL TECHNOL | SEC filing · Form S-3 | SEC EDGAR | +0.71% | -1.80% | |
| Form 8-K CREATIVE MEDICAL TECHNOL For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +2.17% | -7.14% | |
| Form 10-Q CREATIVE MEDICAL TECHNOL For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.63% | +3.15% | |
| Form PRE 14A CREATIVE MEDICAL TECHNOL For: Nov 03 | SEC filing · Form PRE | SEC EDGAR | -2.70% | -3.72% | |
| Form 8-K CREATIVE MEDICAL TECHNOL For: Oct 29 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -4.15% | |
| Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits | Press release | GlobeNewswire | +0.40% | -13.49% | |
| Form DEF 14A CREATIVE MEDICAL TECHNOL For: Oct 27 | SEC filing · Form DEF | SEC EDGAR | +0.40% | -13.49% | |
| Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds | Press release | GlobeNewswire | -3.56% | -29.59% | |
| Creative Medical Technology Holdings Issues Letter to Shareholders | Press release | GlobeNewswire | -1.78% | +1.88% | |
| Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs | Press release | GlobeNewswire | +1.16% | +2.10% | |
| Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain | Press release | GlobeNewswire | -3.00% | -2.12% | |
| Form 10-Q CREATIVE MEDICAL TECHNOL For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -9.03% | |
| Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells | Press release | GlobeNewswire | -1.19% | +3.56% | |
| Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling | Press release | GlobeNewswire | +2.84% | -0.34% | |
| Form 10-Q CREATIVE MEDICAL TECHNOL For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.94% | -6.60% | |
| Form 8-K CREATIVE MEDICAL TECHNOL For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.52% | |
| Form 10-K/A CREATIVE MEDICAL TECHNOL For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -1.01% | |
| Form EFFECT CREATIVE MEDICAL TECHNOL | SEC filing · Form EFFECT | SEC EDGAR | +11.96% | -1.38% | |
| Form 8-K CREATIVE MEDICAL TECHNOL For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | +11.96% | -1.38% | |
| Form 10-K/A CREATIVE MEDICAL TECHNOL For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -8.27% | -5.63% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CELZ section they belong to.
Where else CELZ is measured.
CELZ earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Supreme Cannabis Co Inc (SPRWF) | 105 | -0.13% | 41% |
| Unity Biotechnology, Inc. (UBX) | 105 | 0.00% | 38% |
| COVALON TECHS LTD (CVALF) | 103 | 0.00% | 35% |
| ENCISION INC (ECIA) | 103 | 0.00% | 33% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Creative Medical Technology Holdings, Inc.'s median reaction calculated?
Every labeled CELZ news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 103 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of CELZ's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CELZ's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.